

Special Issue

The Tumor Microenvironment and Immunotherapy of Head and Neck Cancer

Message from the Guest Editor

In recent years, immune checkpoint, adoptive cell transfer, cancer vaccine, and oncolytic virus treatments have all been used to treat cancer. However, due to TEM heterogeneity, treatment responses in cancers are unpredictable even when the same immunotherapy is used. In HNC, HPV infection alters the TEM of the immune cell landscape, resulting in HPV-positive HNC patients having a better prognosis compared to HPV-negative HNC patients. Considering that TME high heterogeneity leads to varying outcomes in immunotherapy patients, a deeper understanding of immune cells in the TME is essential for deciphering immunotherapies mechanisms, defining predictive biomarkers, and discovering novel therapeutic targets. The aim of this Special Issue is to collect original articles and reviews to better understand TME and the immunotherapy of HNC.

Guest Editor

Prof. Dr. Yu-Chao Chang
College of Oral Medicine, Chung-Shan Medical University, Taiwan

Deadline for manuscript submissions

closed (30 November 2023)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/160150

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)